• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Adlai Nortye Ltd.

    10/22/25 5:00:01 PM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANL alert in real time by email
    6-K 1 ea0262091-6k_adlai.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of October 2025

     

    Commission File Number: 001-41773

     

    Adlai Nortye Ltd.

     

    c/o PO Box 309, Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F   ☐ Form 40-F

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    Exhibit 99.1   Notice of Extraordinary General Meeting of Shareholders
    Exhibit 99.2   Proxy Card for Extraordinary General Meeting of Shareholders

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Adlai Nortye Ltd.
         
      By: /s/ Yang Lu
      Name: Yang Lu
      Title: Chief Executive Officer and
        Chairman of Board of Directors

     

    Date: October 22, 2025

     

     

    2

     

    Get the next $ANL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANL

    DatePrice TargetRatingAnalyst
    6/2/2025Buy → Neutral
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    10/24/2023$30.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ANL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adlai Nortye to Participate in Upcoming Investor Conferences

    SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate in the following investor conferences: The 8th Annual Evercore Healthcare ConferenceFormat: Fireside ChatHost: Jonathan MillerDate and Time: Tuesday, December 2, 2025; 4:15 pm - 4:35 PM EST.Location: Sevilla A, Track 2, the Loews Coral Gables Hotel in Coral Gables, Florida. The 36th Oppenheimer Annual Healthcare Life Sciences ConferenceFormat: Virtual Presen

    11/21/25 8:00:00 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. Key highlights of the presentation include: AN4035 demonstrated strong intracellular payload retention, driving nanomolar to picomolar cytotoxicity in CEACAM5-positive/RAS-addicted cancer cell lines, along with a potent bystander-killing effect

    10/22/25 12:00:00 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. Presentation details are as follows: Abstract title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window Date and Time:

    10/13/25 11:07:48 PM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    SEC Filings

    View All

    SEC Form 6-K filed by Adlai Nortye Ltd.

    6-K - Adlai Nortye Ltd. (0001944552) (Filer)

    12/3/25 6:08:30 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Adlai Nortye Ltd.

    6-K - Adlai Nortye Ltd. (0001944552) (Filer)

    10/22/25 5:00:01 PM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Adlai Nortye Ltd.

    S-8 - Adlai Nortye Ltd. (0001944552) (Filer)

    9/15/25 7:45:28 PM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adlai Nortye Ltd. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral

    6/2/25 11:24:27 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Adlai Nortye Ltd. with a new price target

    H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00

    9/4/24 7:16:56 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. with a new price target

    Cantor Fitzgerald initiated coverage of Adlai Nortye Ltd. with a rating of Overweight and set a new price target of $30.00

    10/24/23 6:10:09 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    Leadership Updates

    Live Leadership Updates

    View All

    Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

    SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

    8/8/24 8:00:00 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

    SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear

    3/29/24 6:00:00 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adlai Nortye Ltd.

    SC 13G - Adlai Nortye Ltd. (0001944552) (Subject)

    3/4/24 4:02:34 PM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care